Erenumab-Aooe 140 MG/ML [Aimovig] for migraine disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Jul 2020: Trial registered, NCT04465357
  2. 22 Oct 2020: Trial started, NCT04465357

The trials

NCT04465357: Efficacy of Erenumab on Functional Impact of Migraine

State
Completed
Phase
Phase 4
People
55 taking part
Started
22 Oct 2020
Primary completion
3 Jun 2022
Arms
Erenumab-Aooe 140 MG/ML [Aimovig]
Results
Posted on the registry
  1. 10 Jul 2020: Trial registered
  2. 22 Oct 2020: Trial started
  3. 3 Jun 2022: Trial completed
  4. 5 Oct 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.